Aelis Farma (STU:69O) LT-Debt-to-Total-Asset: 0.43 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:69O Aelis Farma SA STU:69O
37 GF Score
Price €1.02
GF Value €0.85
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aelis Farma LT-Debt-to-Total-Asset?

Aelis Farma STU:69O -1.73% 37 LT-Debt-to-Total-Asset is 0.43 as of Dec. 2025. GuruFocus rates STU:69O with a GF Score™ of 37/100 and a GF Value™ of €0.85 (Modestly Overvalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Aelis Farma's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.43.

Aelis Farma's long-term debt to total assets ratio increased from Dec. 2024 (0.23) to Dec. 2025 (0.43). It may suggest that Aelis Farma is progressively becoming more dependent on debt to grow their business.

Aelis Farma  (STU:69O) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Aelis Farma LT-Debt-to-Total-Asset Related Terms

Aelis Farma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Aelis Farma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aelis Farma LT-Debt-to-Total-Asset Chart

Aelis Farma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only 0.19 0.08 0.11 0.23 0.43

Aelis Farma Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.19 0.23 0.31 0.43
STU:69O
37GF Score
Aelis Farma SA STU:69O
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aelis Farma LT-Debt-to-Total-Asset Calculation

Aelis Farma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=5.17/12.048
=

Aelis Farma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=5.17/12.048
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.43 mean?
Aelis Farma (STU:69O) has a LT-Debt-to-Total-Asset of 0.43 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Aelis Farma and its competitors.
Is Aelis Farma's LT-Debt-to-Total-Asset too high?
Aelis Farma's current LT-Debt-to-Total-Asset is 0.43. Overall, Aelis Farma has a GF Score™ of 37/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aelis Farma's LT-Debt-to-Total-Asset compare to VRTX and REGN?
Aelis Farma's LT-Debt-to-Total-Asset of 0.43 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Aelis Farma and its competitors. Aelis Farma's current LT-Debt-to-Total-Asset is 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aelis Farma stock overvalued right now?
Based on GuruFocus' analysis, Aelis Farma (STU:69O) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.85, compared to a current price of €1.02 — trading 20.5% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.43. Aelis Farma's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Aelis Farma (STU:69O), the current LT-Debt-to-Total-Asset is 0.43 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aelis Farma (STU:69O) Overvalued in 2026?

Based on GuruFocus' analysis, Aelis Farma stock appears to be overvalued. The current stock price of €1.02 is trading 20.5% above its estimated GF Value™ of €0.85. GuruFocus considers Aelis Farma to be Modestly Overvalued.

Key valuation signals for STU:69O:

  • LT-Debt-to-Total-Asset: 0.43
  • GF Value™: €0.85 vs. price of €1.02 (20.5% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the STU:69O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aelis Farma Business Description

Other Exchanges AELIS:France69O:Germany
Address 2 rue Robert Escarpit, IECB, Pessac, Bordeaux, FRA, 33607
Aelis Farma SA is a biotechnology Company specializing in the research and development of treatment's related to brain diseases. The Company operates in only one business segment: the research and development of pharmaceutical products.
37GF Score

Get the complete analysis for STU:69O

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.02
Price
€0.85
GF Value